BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32572914)

  • 1. Protective effect of the RNA-binding protein RBM10 in hepatocellular carcinoma.
    Zhao Z; Li J; Shen F
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6005-6013. PubMed ID: 32572914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-binding protein RBM6 acts as a tumor suppressor gene to inhibit the progression of hepatocellular carcinoma.
    Ye Z; Zhang J; Yang Y; Wei Y; Li L; Wang X
    J BUON; 2021; 26(2):402-408. PubMed ID: 34076986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma progression is protected by miRNA-34c-5p by regulating FAM83A.
    Yu WS; Wang ZG; Guo RP; Lin ZQ; Ye ZW; Lu CL
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6046-6054. PubMed ID: 32572919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
    Liu FH; Cui YP; He YK; Shu RH
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma.
    Tang H; Zhang J; Yu Z; Ye L; Li K; Ding F; Feng X; Meng W
    Technol Cancer Res Treat; 2017 Dec; 16(6):1136-1149. PubMed ID: 29332449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
    Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-328-3p inhibits malignant progression of hepatocellular carcinoma by regulating MMP-9 level.
    Li JZ; Li J; Liu BZ
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9331-9340. PubMed ID: 31773692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.
    Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of microRNA-7 on proliferation and invasion of hepatocellular carcinoma HepG2 cells].
    Qin AD; Liu XX; Li J; Liu J; Li YS
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):406-411. PubMed ID: 29936764
    [No Abstract]   [Full Text] [Related]  

  • 13. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
    Li SJ; Sui MH; Sun ZX; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.
    Sun SJ; Wang N; Sun ZW; Chen J; Cui HW
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4869-4878. PubMed ID: 30070322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway.
    Wu JH; Tian XY; An QM; Guan XY; Hao CY
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1645-1652. PubMed ID: 29630107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of long noncoding RNA linc00261 in hepatocellular carcinoma and its association with postoperative outcomes].
    Chen Z; Xiang L; Huang Y; Fang Y; Li X; Yang D
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1179-1186. PubMed ID: 30377132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TPM4 aggravates the malignant progression of hepatocellular carcinoma through negatively regulating SUSD2.
    Sheng ZG; Chen MH
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4756-4765. PubMed ID: 32432739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
    Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
    EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of GCF2/LRRFIP1 by RNAi causes cell growth inhibition and increased apoptosis in human hepatoma HepG2 cells.
    Li JP; Cao NX; Jiang RT; He SJ; Huang TM; Wu B; Chen DF; Ma P; Chen L; Zhou SF; Xie XX; Luo GR
    Asian Pac J Cancer Prev; 2014; 15(6):2753-8. PubMed ID: 24761896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.